{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 460024985
| IUPAC_name = (6''R'',7''R'')-7-<nowiki>[[</nowiki>(2''Z'')-2-(5-amino-1,2,4-thiadiazol-3-ylidene)- 2-nitroso-1-oxoethyl]amino]-8-oxo-3-[(''E'')-[2-oxo-1-[(3''R'')- 3-pyrrolidinyl]-3-pyrrolidinylidene]methyl]-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| image = Ceftobiprole2DCSD.svg
| width = 300px

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|ceftobiprole}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Marketed in the UK, France, Italy, Germany, Austria, Switzerland
| routes_of_administration = Intravenous

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 209467-52-7
| CAS_supplemental = <br/>{{CAS|252188-71-9}} (medocaril)
| ATC_prefix = J01
| ATC_suffix = DI01
| ATC_supplemental = <ref>{{cite web|url=http://www.whocc.no/atcddd/new_atc_ddd.html#ATCDDD_FINAL |title=ATC/DDD Classification (FINAL): New ATC 5th level codes |date=August 27, 2008 |author=WHO International Working Group for Drug Statistics Methodology |publisher=WHO Collaborating Centre for Drug Statistics Methodology |accessdate=2008-09-05 |deadurl=yes |archiveurl=https://web.archive.org/web/20080506023243/http://www.whocc.no/atcddd/new_atc_ddd.html#ATCDDD_FINAL |archivedate=2008-05-06 |df= }}</ref>
| PubChem = 6918430
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5T97333YZK
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08885
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 520642
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 23350302
<!--Chemical data-->
| C=20 | H=22 | N=8 | O=6 | S=2 
| molecular_weight = 534.568 g/mol
| smiles = C1CNC[C@@H]1N2CC/C(=C\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\O)/c5nc(sn5)N)SC3)C(=O)O)/C2=O
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = VOAZJEPQLGBXGO-SDAWRPRTSA-N
}}
{{expert|subject=药学|time=2019-03-31T16:08:59+00:00}}
'''头孢比普'''（Ceftobiprole）是用于{{le|社区型获得肺炎|Community-acquired pneumonia}}的第五代[[头孢菌素|头孢菌素]]。{{le|Basilea藥廠|Basilea Pharmaceutica}}在英國、德國、瑞士及奧地利上市的商品名為Mabelio，而法國及義大利的商品名是Mabelio<ref>{{Cite web|title=Basilea Pharmaceutica - News and Media|url=http://www.basilea.com/News-and-Media/Basilea-to-launch-Zevtera-Mabelio-ceftobiprole-medocaril-in-Europe-through-a-commercial-services-provider/7dcfb10b-c4ef-5a82-8359-f88b1f36cb96/|work=www.basilea.com|accessdate=2019-03-31}}</ref>。

==参考资料==
{{reflist}}
{{细胞壁破坏性抗生素}}
{{藥學小作品}}
[[Category:頭孢菌素|Category:頭孢菌素]]
[[Category:抗生素|Category:抗生素]]